Zydus Lifesciences Limited — Updates, 19-05-2026: Press Release

Zydus Lifesciences delivered strong quarterly and full-year results. Quarterly revenue grew 16% to 7,587 Cr, EBITDA 20% to 2,554 Cr. The board declared a 100% dividend and approved a 1,100 Cr share buyback. Key launches and a US$166 million acquisition of Assertio Holdings strengthen the portfolio.